Recommended NZ | Guide to Money | Gimme: Competitions - Giveaways

Appointment of Botanix Executive Director, Dr Michael Thurn

Fuseworks Media
Fuseworks Media

Medical dermatology company Botanix Pharmaceuticals Limited is pleased to announce the appointment of its Head of Australian Operations, Dr Michael Thurn, as an Executive Director - a well deserved and welcome extension of his existing remit within the leadership team.

Dr Thurn has over two decades of experience in the life sciences and biotechnology industry and has accumulated extensive knowledge in drug regulation, drug discovery, pre-clinical and clinical development across dermatology in Australia and the United States. He has held various senior executive, managerial and Board positions in both listed and private companies and brings unique experience, highly relevant technical knowledge and complementary skillset to the Botanix Board.

Previously, Dr Thurn has worked with the Therapeutic Goods Administration in Australia, led the clinical development of a topical acne treatment through to completion of Phase 2 clinical trial and also led Spinifex Pharmaceuticals, which was sold to Novartis in a $700m transaction.

All articles and comments on have been submitted by our community of users. Please notify us if you believe an item on this site breaches our community guidelines.